Capecitabine Improves Outcomes in TNBC When Added to Other Systemic Therapy

TOP - July 2020, Vol 13, No 4 - Breast Cancer
Phoebe Starr

San Antonio, TX—Although capecitabine (Xeloda) is approved for metasta­tic breast cancer, it is not clear whether it should be used in early breast cancer, and its optimal role remains to be established. A large meta-analysis sheds some light on this issue, demonstrating that capecitabine improves disease-free survival (DFS) and overall survival (OS) for patients with triple-negative breast cancer (TNBC) when added to other systemic therapies, but not as a substitute for other therapies.

“Capecitabine [alone] did not alter overall DFS, but when added to other systemic therapies there was an improvement. Overall survival was also improved when capecitabine was given in addition to other therapies. There is no evidence supporting a predictive value of capecitabine-specific adverse events on outcome. It can be concluded that the addition of capecitabine to other treatment may be recommended for TNBC patients,” stated lead investigator Marion van Mackelenbergh, MD, Universitätsklinikum Schleswig-Holstein, Kiel, Germany, at last year’s San Antonio Breast Cancer Symposium.

This is a “major finding,” noted Harold J. Burstein, MD, PhD, Institute Physician, Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, in an online post. “We have undervalued this approach, because all-comers trials rarely showed a benefit.”

This meta-analysis did not compare the effects of capecitabine with carboplatin in patients with TNBC. Studies are needed in early breast cancer to compare capecitabine with other systemic therapies, including carboplatin.

New Data from >15,000 Patients

The meta-analysis included data from 15,457 patients enrolled in 12 randomized controlled trials; 7893 patients with early breast cancer received treatment with capecitabine, and 7477 patients were in the control arms. Of the studies included in the meta-analysis, 5 addressed treatment with capecitabine used instead of other therapies, and 7 evaluated capecitabine in addition to other therapies. The evaluable population for DFS totaled 4097 patients.

The analysis was performed on the overall study population, as well as on 2 predefined groups, including patients who received capecitabine in addition to other therapies and those who received capecitabine instead of another systemic treatment.

A total of 74.3% of the study patients had nodal involvement; 56% presented with stage II disease; approximately 68% had hormone receptor–positive disease; 45% had high-grade disease; and 15% had HER2-positive disease. Approximately 80% of the studies were conducted in the adjuvant setting, and almost 20% were conducted in the neoadjuvant setting.

In the overall analysis, no significant effect was seen of capecitabine on DFS. However, among patients who received capecitabine in addition to other therapies, a significant DFS benefit was observed (hazard ratio [HR], 0.888).

Benefit Limited to Patients with TNBC

“Of all the trials, only the FinXX and CREATE-X trials [in the meta-analysis] had positive results for DFS, and no benefit of capecitabine on DFS was observed when capecitabine was given instead of another treatment,” Dr van Mackelenbergh noted.

A modest OS benefit for capecitabine was observed for the total data set (HR, 0.892), and the OS benefit was more robust when capecitabine was added to other systemic therapies (HR, 0.837).

“CREATE-X was the only trial that was positive for OS. There was no OS benefit when capecitabine was substituted for another systemic therapy,” Dr van Mackelenbergh emphasized.

In patients with TNBC, capecitabine improved the OS by 22% and the DFS rate by 18% when added to standard chemotherapy (P = .004 for both). No benefit was observed in TNBC when capecitabine was given instead of another systemic therapy.

An analysis performed according to disease biologic subtype showed an overall OS benefit for capecitabine in patients with TNBC (HR, 0.828) and when capecitabine was added to other therapies in TNBC (HR, 0.778).

“Since the publication of the CREATE-X results, capecitabine has been a reasonable option for TNBC. The meta-analysis results support this. There is no benefit in the estrogen receptor–positive patients, and the benefit is limited to the TNBC population,” said Steven Isakoff, MD, PhD, Medical Oncologist, Center for Breast Cancer, Massachusetts General Hospital Cancer Center, Boston.

The most common grades 3 and 4 toxicities with capecitabine were mucositis, hand-foot syndrome, and diarrhea. No significant associations were reported between capecitabine-specific toxicities and treatment benefit.

Related Items
Breast Cancer Year in Review Introduction
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Retrospective Analysis Provides Insight into Treatment-Emergent Neutropenia Among Patients with Metastatic Breast Cancer Treated with Ribociclib or Palbociclib
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Concurrent Use of Medications with Potential Drug–Drug Interactions: Real-World Analysis of Patients Treated with CDK4/6 Inhibitors
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Abemaciclib plus Fulvestrant Provides Statistically Significant Benefit as First- and Second-Line Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Preliminary Results from a Phase 2 Trial of Fulvestrant/Palbociclib as First-Line Therapy in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Endocrine-Sensitive Advanced Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Ribociclib Added to Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Demonstrated Favorable Quality-of-Life Results
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Examining Different Sequence Effects of CDK4/6 Inhibitor Combinations on Actual Real-World Outcomes of Treatment in Patients with Hormone Receptor–Positive and HER2-Negative Metastatic Breast Cancer
2020 Year in Review - Breast Cancer published on January 24, 2021 in Breast Cancer
Benefit of Alpelisib When Combined with Fulvestrant as Demonstrated Through Biomarker Subanalysis from the SOLAR-1 Study
2020 Year in Review - Breast Cancer published on January 20, 2021 in Breast Cancer
Efficacy Outcomes of Platinum-Based Chemotherapy in Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
2020 Year in Review - Breast Cancer published on January 20, 2021 in Breast Cancer
Retrospectively Analyzing the Use of CDK4/6 Inhibitors to Treat Adult Female Patients with Metastatic Breast Cancer
2020 Year in Review - Breast Cancer published on January 20, 2021 in Breast Cancer
Last modified: October 30, 2020